Radiation Oncology Department of Thoracic Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District Shenyang, Liaoning Province 110042, PR China.
Biomark Med. 2020 Oct;14(14):1341-1352. doi: 10.2217/bmm-2019-0583. Epub 2020 Aug 18.
To determine whether pretreatment of neutrophil-to-lymphocyte ratio (NLR) or platelet-to-lymphocyte ratio (PLR) has a prognostic value in patients with inoperable locally advanced non-small-cell lung cancer. A total of 167 patients between 2013 and 2016 were analyzed retrospectively. Appropriate cut-off values for initial NLR (3.06) and PLR (168.03) were determined by receiver operating characteristic curves. High NLR (p < 0.001 and p < 0.001) was related to poor overall survival (OS) and progression-free survival (PFS) via univariate analysis. Multivariable analysis showed that NLR can independently influence OS (hazard ratio: 1.570; p = 0.012) and PFS (hazard ratio: 1.471; p = 0.023). PLR did not correlate with OS or PFS. Pretreatment of NLR could independently predict the prognosis of inoperable locally advanced non-small-cell lung cancer patients, while pretreatment of PLR does not have prognostic value.
为了确定中性粒细胞与淋巴细胞比值（NLR）或血小板与淋巴细胞比值（PLR）预处理在不可手术局部晚期非小细胞肺癌患者中的预后价值。回顾性分析了 2013 年至 2016 年间的 167 例患者。通过受试者工作特征曲线确定初始 NLR（3.06）和 PLR（168.03）的适当截止值。单因素分析显示，高 NLR（p<0.001 和 p<0.001）与总生存（OS）和无进展生存（PFS）不良相关。多变量分析表明，NLR 可独立影响 OS（风险比：1.570；p=0.012）和 PFS（风险比：1.471；p=0.023）。PLR 与 OS 或 PFS 无关。NLR 预处理可独立预测不可手术局部晚期非小细胞肺癌患者的预后，而 PLR 预处理无预后价值。
